More recently, the DAPA-MI and EMPACT-MI trials have expanded this concept by showing that SGLT2 inhibitors may also provide significant cardioprotective effects in patients with recent myocardial infarction, even in the absence of T2D, further supporting a broader role of this drug class in cardiovascular prevention [12,13]. Here, SLC5A2 is linked to type 2 diabetes mellitus.